Institute of Health Sciences, Medical College, Rzeszow University, 35-959 Rzeszow, Poland.
Institute of Medicine, Medical College, Rzeszow University, 35-959 Rzeszow, Poland.
Int J Mol Sci. 2024 May 11;25(10):5238. doi: 10.3390/ijms25105238.
Currently, metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are considered to be the main causes of fibrosis. In turn, fibrosis may lead to the development of hepatocellular carcinoma or advanced cirrhosis, i.e., potentially life-threatening conditions. It is likely that therapy aimed at reducing the risk of developing hepatic steatosis and inflammation could be helpful in minimizing the threat/probability of organ fibrosis. In recent years, increasing attention has been paid to the influence of nutraceuticals in the prevention and treatment of liver diseases. Therefore, the aim of this review was to describe the precise role of selected ingredients such as vitamin C, beta-carotene, omega-3 fatty acids, and curcumin. It is likely that the use of these ingredients in the treatment of patients with MASLD/MASH, along with behavioral and pharmacological therapy, may have a beneficial effect on combating inflammation, reducing oxidative stress, and thereby preventing liver damage.
目前，代谢功能障碍相关脂肪性肝病（MASLD）和代谢功能障碍相关脂肪性肝炎（MASH）被认为是纤维化的主要原因。反过来，纤维化可能导致肝细胞癌或晚期肝硬化的发展，即潜在的危及生命的情况。因此，旨在降低肝脂肪变性和炎症风险的治疗方法可能有助于最大限度地降低器官纤维化的威胁/可能性。近年来，人们越来越关注营养保健品在预防和治疗肝脏疾病方面的作用。因此，本综述的目的是描述维生素 C、β-胡萝卜素、ω-3 脂肪酸和姜黄素等选定成分的确切作用。这些成分在 MASLD/MASH 患者的治疗中与行为和药物治疗联合使用，可能对对抗炎症、减轻氧化应激从而预防肝损伤产生有益的效果。
